Neumora Therapeutics Inc
NMRA1.687USD
+0.127+8.17%
Horário de mercado （ET）Cotações atrasadas em 15 min
272.93MValor de mercado
PerdaP/L TTM
Mais detalhes de Neumora Therapeutics Inc Empresa
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Informações da empresa
Código da empresaNMRA
Nome da EmpresaNeumora Therapeutics Inc
Data de listagemSep 15, 2023
CEOMr. Paul L. Berns
Número de funcionários110
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 15
Endereço490 Arsenal Way
CidadeWATERTOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02472
Telefone18577600900
Sitehttps://neumoratx.com/
Código da empresaNMRA
Data de listagemSep 15, 2023
CEOMr. Paul L. Berns
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.68M
+3.27%
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
130.51K
+46.75%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
27.62K
--
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
22.47K
-8.09%
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Jason G. Duncan
Mr. Jason G. Duncan
Chief Legal and Administrative Officer
Chief Legal and Administrative Officer
--
--
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.68M
+3.27%
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
130.51K
+46.75%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
27.62K
--
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
22.47K
-8.09%
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Amgen Inc
21.87%
ARCH Venture Partners
19.74%
Berns (Paul L)
4.75%
SB Global Advisers Ltd
4.04%
BlackRock Institutional Trust Company, N.A.
3.49%
Other
46.11%
Investidores
Investidores
Proporção
Amgen Inc
21.87%
ARCH Venture Partners
19.74%
Berns (Paul L)
4.75%
SB Global Advisers Ltd
4.04%
BlackRock Institutional Trust Company, N.A.
3.49%
Other
46.11%
Tipos de investidores
Investidores
Proporção
Investment Advisor
24.47%
Corporation
21.87%
Venture Capital
21.03%
Investment Advisor/Hedge Fund
6.00%
Individual Investor
5.65%
Hedge Fund
3.95%
Endowment Fund
2.05%
Research Firm
1.66%
Bank and Trust
1.40%
Other
11.93%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
286
142.72M
88.23%
-24.78M
2025Q1
283
144.00M
90.43%
+12.16M
2024Q4
249
161.18M
99.54%
+45.20M
2024Q3
201
148.65M
93.66%
+40.67M
2024Q2
179
142.61M
90.03%
+47.65M
2024Q1
154
133.89M
85.01%
+50.39M
2023Q4
108
122.49M
78.90%
+50.97M
2023Q3
54
110.63M
71.42%
+110.63M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Amgen Inc
35.37M
21.87%
--
--
Apr 10, 2025
ARCH Venture Partners
31.93M
19.74%
--
--
Nov 12, 2024
Berns (Paul L)
7.68M
4.75%
+242.77K
+3.27%
Apr 10, 2025
SB Global Advisers Ltd
6.54M
4.04%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.65M
3.49%
-433.37K
-7.13%
Mar 31, 2025
The Vanguard Group, Inc.
5.33M
3.29%
+766.67K
+16.82%
Mar 31, 2025
Invus Public Equities Advisors, LLC
4.36M
2.69%
-37.82K
-0.86%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.50M
2.16%
-4.23M
-54.72%
Mar 31, 2025
Wellcome Trust
3.31M
2.05%
--
--
Mar 31, 2025
ICONIQ Capital, LLC
2.56M
1.58%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0%
ALPS Medical Breakthroughs ETF
0%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0%
iShares Russell 3000 ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Ver Mais
ProShares Ultra Nasdaq Biotechnology
Proporção0.01%
Invesco Nasdaq Biotechnology ETF
Proporção0.01%
iShares Biotechnology ETF
Proporção0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0%
ALPS Medical Breakthroughs ETF
Proporção0%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção0%
iShares Russell 3000 ETF
Proporção0%
Schwab U.S. Small-Cap ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
